SCHEMBL5565822

SCHEMBL5565822

COc1cc(OC)c(-c2cc3ccccc3n2C)cc1C=CC(=O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.46
TNFRSF1A P19438 6/20 0.45
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAOB P27338 1/20 0.41
P4HB P07237 1/20 0.41
DPP4 P27487 3/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565821 1.00 ABCG2 (0.46) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5561063 0.89 ABCG2 (0.47) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5561058 0.89 ABCG2 (0.47) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5565585 0.88 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5566293 0.88 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5565583 0.88 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5566296 0.88 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5565782 0.87 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL5565785 0.87 MAPT (0.49) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2
SCHEMBL6040704 0.86 ABCG2 (0.52) ABCG2TNFRSF1ALMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 ABCG2 7/4885TNFRSF1A 3941/4885LMNA 2762/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 ABCG2 7/4885TNFRSF1A 3941/4885LMNA 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.